Last reviewed · How we verify
Idaltim (CORTIVAZOL)
Idaltim (generic name: CORTIVAZOL) is a cortivazol drug. It is currently in Phase 2 development.
Cortivazol works by binding to the glucocorticoid receptor, which helps regulate the immune system.
Idaltim, also known as cortivazol, is a small molecule that acts as a glucocorticoid receptor agonist. It has been studied in clinical trials for various conditions, including lumbar disk herniation, discal sciatica, plantar fascitis, and cluster headache.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CORTIVAZOL |
|---|---|
| Drug class | cortivazol |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
Imagine your immune system as a fire alarm that sounds when it detects danger. Cortivazol helps calm down the alarm by binding to the receptor that triggers the alarm, reducing inflammation and immune response.
Approved indications
Common side effects
Key clinical trials
- Effectiveness of Lumbar Traction in Lumbar Disk Herniation (NA)
- Efficacy of Platelet Rich Plasma in Plantar Fasciitis (NA)
- Comparison of a Cortivazol (ALTIM®) Infiltration of Posterior Epidural Space at L3-L4 Stage Versus an Epidural Infiltration of Cortivazol (ALTIM®) on Contact With Disco Radicular Conflict in Discal Sciatica (PHASE3)
- Cluster Headache Cortivazol Injection (CHCI) (PHASE2,PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Idaltim CI brief — competitive landscape report
- Idaltim updates RSS · CI watch RSS
Frequently asked questions about Idaltim
What is Idaltim?
How does Idaltim work?
What is the generic name of Idaltim?
What drug class is Idaltim in?
What development phase is Idaltim in?
What does Idaltim target?
Related
- Drug class: All cortivazol drugs
- Target: All drugs targeting Glucocorticoid receptor
- Therapeutic area: All drugs in Immunology
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing